42 related articles for article (PubMed ID: 9441773)
1. Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies.
Akhavan D; Yazaki P; Yamauchi D; Simpson J; Frankel PH; Bading J; Colcher D; Poku K; Chen YJ; Lim D; Cristea M; Wu A; Shively J; Wong JYC
Cancer Biother Radiopharm; 2020 Feb; 35(1):10-15. PubMed ID: 31910346
[No Abstract] [Full Text] [Related]
2. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma.
Chan SY; Gordon AN; Coleman RE; Hall JB; Berger MS; Sherman ML; Eten CB; Finkler NJ
Cancer Immunol Immunother; 2003 Apr; 52(4):243-8. PubMed ID: 12669249
[TBL] [Abstract][Full Text] [Related]
3. Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-labeled Hepama-1 mAb. Preliminary results and discussion.
Zeng ZC; Tang ZY; Liu KD; Lu JZ; Cai XJ; Xie H
Cancer Immunol Immunother; 1994 Nov; 39(5):332-6. PubMed ID: 7987865
[TBL] [Abstract][Full Text] [Related]
4. Non-human primate (baboon) anti-carcinoembryonic antigen antibody infusion in patients with metastatic adenocarcinoma. A phase I study.
Huberman MS; Lokich JJ; Hill T; Kaldany A; Kassis A; Price T; Moore C; Davis S; Kasulis P; Monaco AP
Cancer Immunol Immunother; 1986; 23(2):137-42. PubMed ID: 3490911
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients.
Wang H; Cao C; Li B; Chen S; Yin J; Shi J; Ye D; Tao Q; Hu P; Epstein A; Ju D
Cancer Immunol Immunother; 2008 May; 57(5):677-84. PubMed ID: 17934732
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis.
Derrien A; Gouard S; Maurel C; Gaugler MH; Bruchertseifer F; Morgenstern A; Faivre-Chauvet A; Classe JM; Chérel M
Front Med (Lausanne); 2015; 2():88. PubMed ID: 26734610
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of solid tumors: searching for the right target.
Song H; Sgouros G
Curr Drug Deliv; 2011 Jan; 8(1):26-44. PubMed ID: 21034423
[TBL] [Abstract][Full Text] [Related]
9. Use of antibodies and immunoconjugates for the therapy of more accessible cancers.
Sharkey RM; Goldenberg DM
Adv Drug Deliv Rev; 2008 Sep; 60(12):1407-20. PubMed ID: 18508155
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody-directed cytotoxic therapy: potential in malignant diseases of aging.
Panousis C; Pietersz GA
Drugs Aging; 1999 Jul; 15(1):1-13. PubMed ID: 10459728
[TBL] [Abstract][Full Text] [Related]
11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
12. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
13. Milestones in the development of Lym-1 therapy.
DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
[TBL] [Abstract][Full Text] [Related]
14. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
[TBL] [Abstract][Full Text] [Related]
15. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.
Juweid M; Sharkey RM; Alavi A; Swayne LC; Herskovic T; Hanley D; Rubin AD; Pereira M; Goldenberg DM
J Nucl Med; 1997 Feb; 38(2):257-60. PubMed ID: 9025751
[TBL] [Abstract][Full Text] [Related]
16. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
